Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

primary immunodeficiency diseases/protease

Le lien est enregistré dans le presse-papiers
Page 1 de 71 résultats
RELATED APPLICATION This is a .sctn.371 of International Application No. PCT/FR2005/001356, with an international filing date of Jun. 2, 2005 (WO 2006/000693 A1, published Jan. 5, 2006), which is based on French Patent Application No. 04/05945, filed Jun. 2, 2004. TECHNICAL FIELD This disclosure
FIELD OF THE INVENTION This invention relates to a method of treating human immunodeficiency virus (HIV) infection in a mammal comprising administering to the mammal a therapeutically effective amount of a combination of: (i) at least one cyclic HIV protease inhibitor and (ii) at least one HIV

Human immunodeficiency virus protease inhibitors

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF INVENTION The described invention relates to novel human immunodeficiency virus protease inhibitors, pharmaceutical compositions containing at least one such inhibitor, methods of preparing such inhibitors, and methods of utilizing such inhibitors to treat HIV and HIV-related

Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to formulations of nanoparticulate human immunodeficiency virus (HIV) protease inhibitor drug substances comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of

Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to formulations of nanoparticulate human immunodeficiency virus (HIV) protease inhibitor drug substances comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of

Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to formulations of nanoparticulate human immunodeficiency virus (HIV) protease inhibitor drug substances comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of

Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION The present invention relates generally to the field of treatment human beings with Human Immunodeficiency Virus (HIV) infections. The inventors have found that the combination of hydroxyurea (HU), a nucleoside analog, and a protease inhibitor is capable of reducing the

Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION The present invention relates generally to the field of treatment of human beings with Human Immunodeficiency Virus (HIV) infections. The inventors have found that the combination of hydroxyurea (HU), a nucleoside analog, and a protease inhibitor is capable of reducing the

Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
CROSS REFERENCE TO RELATED APPLICATION This is a National Stage of International Application No. PCT/EP2010/067851, filed 19 Nov. 2010, which claims the benefit of application Ser. No. 09/176,666.7, filed in Europe on 20 Nov. 2009, the disclosures of which Applications are incorporated by reference

Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF INVENTION The present invention relates to novel schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV), which is responsible for the acquired immune deficiency syndrome (AIDS). BACKGROUND The human

Use of HIV protease inhibiting compounds

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION The subject of the present invention is the therapeutic use of a human immunodeficiency virus (HIV) protease inhibiting compound as proteasome modulator. DESCRIPTION OF RELATED ART Proteasome, a central enzymatic system in protein degradation both in the cytosol and in the

Process for preparing protease inhibitor intermediates

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION The present invention generally concerns the preparation of cyclic alcohol intermediates useful in the preparation of inhibitors of HIV aspartyl protease. More specifically, the present invention includes a method for the preparation of

Aspartyl protease inhibitors

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,

Use of amphotericin B derivatives as protease inhibitors

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The present invention relates to the use of derivatives of polyene macrolides, in particular amphotericin B, as protease inhibitors, and to the applications of said inhibitors for the production of medicinal products intended in particular for the treatment of infection by the human immunodeficiency

Heterocyclic aspartyl protease inhibitors

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION This invention relates to heterocyclic aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human
Rejoignez notre
page facebook

La base de données d'herbes médicinales la plus complète soutenue par la science

  • Fonctionne en 55 langues
  • Cures à base de plantes soutenues par la science
  • Reconnaissance des herbes par image
  • Carte GPS interactive - étiquetez les herbes sur place (à venir)
  • Lisez les publications scientifiques liées à votre recherche
  • Rechercher les herbes médicinales par leurs effets
  • Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets

Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées

Google Play badgeApp Store badge